Notably, m6Ascore predicts immunotherapy response, with low scores linked to enhanced anti-PD-1/PD-L1 efficacy, suggesting m6A modifications as valuable biomarkers for tailoring endometrial cancer treatments [102, 128]. The gene discussed is CD274; the disease is endometrial cancer.